EBV Peptide-Derived Vaccine Significantly Enhanced In Vitro Cytotoxicity Against EBV-Positive B-Cell Lymphoma (EBV-BL) Treatment Using TMV-Based Delivery System

Authors

Aradhana A. Tiwari, New York Medical College
Alison McCormick
Dina Edani, New York Medical College
Aaron Newman
Christeen Azmy, New York Medical College
Janet Ayello, New York Medical CollegeFollow
Christian KleinFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty, Resident/Fellow

Document Type

Abstract

Publication Date

7-2018

DOI

10.1158/1538-7445.AM2018-2565

Journal Title

Cancer Research

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Tiwari, A. A., McCormick, A., Edani, D., Newman, A., Azmy, C., Ayello, J., Klein, C., & Cairo, M. S. (2018). EBV Peptide-Derived Vaccine Significantly Enhanced In Vitro Cytotoxicity Against EBV-Positive B-Cell Lymphoma (EBV-BL) Treatment Using TMV-Based Delivery System. Cancer Research, 78 (13 Suppl.), 2565. https://doi.org/10.1158/1538-7445.AM2018-2565